ArticleCritical care medicine2021
Core Outcome Measures for Trials in People With Coronavirus Disease 2019: Respiratory Failure, Multiorgan Failure, Shortness of Breath, and Recovery.
Article in Critical care medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pooled it
- Risk Factors for Pediatric Critical COVID-19: A Systematic Review and Meta-Analysis.Journal of the Pediatric Infectious Diseases Society · 2024Pooled it
- Incidence and Outcomes of COVID-19 in People With CKD: A Systematic Review and Meta-analysis.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2021Pooled it
- Health-related quality of life profiles and trajectories of patients with post COVID-19 condition: a latent Markov model.Archives of public health = Archives belges de sante publique · 2026Article
- Developing a Core Outcome Measurement Set for Adult ICU Patients, the CoreMS-ICU-A Protocol.Acta anaesthesiologica Scandinavica · 2026Article
- Impact of Frailty on Prognosis and Functional Outcome in Patients With Acute Respiratory Deterioration of Interstitial Lung Disease.Pulmonary medicine · 2026Observational
- Long-Term Illness in Adults Hospitalized for Respiratory Syncytial Virus Disease, United States, February 2022-September 2023.Emerging infectious diseases · 2025Article
- Take charge after long COVID: a mixed methods randomised controlled pilot study protocol.Annals of medicine · 2025Article
- Long-term multidimensional patient-centred outcomes after hospitalisation for COVID-19: do not only focus on disease severity.BMJ open respiratory research · 2025Article
- Health outcomes up to 3 years and post-exertional malaise in patients after hospitalization for COVID-19: a multicentre prospective cohort study (CO-FLOW).The Lancet regional health. Europe · 2025Article
- Ashwagandha (BMJ open · 2025Article
- Article
- Long-term health outcomes of COVID-19 in ICU- and non-ICU-treated patients up to 2 years after hospitalization: a longitudinal cohort study (CO-FLOW).Journal of intensive care · 2024Article
- Prevalence, risk factors, and impact of long COVID in a socially vulnerable community in Brazil: a prospective cohort study.Lancet regional health. Americas · 2024Article
- Post-covid-19 conditions in adults: systematic review and meta-analysis of health outcomes in controlled studies.BMJ medicine · 2024Article
- The role of convalescent plasma and hyperimmune immunoglobulins in the COVID-19 pandemic, including implications for future preparedness.Frontiers in immunology · 2024Review
- COVID-19 outcome is not affected by anti-CD20 or high-titer convalescent plasma in immunosuppressed patients.Scientific reports · 2023Article
- Prevalence of Long-term Symptoms Varies When Using Different Post-COVID-19 Definitions in Positively and Negatively Tested Adults: The PRIME Post-COVID Study.Open forum infectious diseases · 2023Article
- Recovery and symptom trajectories up to two years after SARS-CoV-2 infection: population based, longitudinal cohort study.BMJ (Clinical research ed.) · 2023Article
- Two-year follow-up of patients with post-COVID-19 condition in Sweden: a prospective cohort study.The Lancet regional health. Europe · 2023Article
Corrections and comments
- Commented on by
Authors and funding
47 authors.
Funding
Abstract
objectivesRespiratory failure, multiple organ failure, shortness of breath, recovery, and mortality have been identified as critically important core outcomes by more than 9300 patients, health professionals, and the public from 111 countries in the global coronavirus disease 2019 core outcome set initiative. The aim of this project was to establish the core outcome measures for these domains for trials in coronavirus disease 2019.
designThree online consensus workshops were convened to establish outcome measures for the four core domains of respiratory failure, multiple organ failure, shortness of breath, and recovery.
settingInternational. PATIENTS: About 130 participants (patients, public, and health professionals) from 17 countries attended the three workshops.
interventionsNone. MEASUREMENTS AND MAIN
resultsRespiratory failure, assessed by the need for respiratory support based on the World Health Organization Clinical Progression Scale, was considered pragmatic, objective, and with broad applicability to various clinical scenarios. The Sequential Organ Failure Assessment was recommended for multiple organ failure, because it was routinely used in trials and clinical care, well validated, and feasible. The Modified Medical Research Council measure for shortness of breath, with minor adaptations (recall period of 24 hr to capture daily fluctuations and inclusion of activities to ensure relevance and to capture the extreme severity of shortness of breath in people with coronavirus disease 2019), was regarded as fit for purpose for this indication. The recovery measure was developed de novo and defined as the absence of symptoms, resumption of usual daily activities, and return to the previous state of health prior to the illness, using a 5-point Likert scale, and was endorsed.
conclusionsThe coronavirus disease 2019 core outcome set recommended core outcome measures have content validity and are considered the most feasible and acceptable among existing measures. Implementation of the core outcome measures in trials in coronavirus disease 2019 will ensure consistency and relevance of the evidence to inform decision-making and care of patients with coronavirus disease 2019.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.